The use of a wearable exercise tracker can improve walking distance and quality of life in patients suffering from intermittent claudication at six months, a study has shown. Results of the randomised wSTEP (Wearable sensor technology efficacy in peripheral vascular disease) trial were presented at the British Society of Endovascular Therapy Annual Meeting (BSET; 2–3 July, Walton Hall, UK).
New 12-month clinical trial outcomes assessing the safety and performance of the Eluvia drug-eluting vascular stent system (Boston Scientific) reflect a primary patency rate of more than 96%.
Bolton Medical has received the CE mark for the Treo abdominal stent graft system used to treat abdominal aortic aneurysms (AAAs).
A new peer reviewed article e-published in the Journal of Vascular Surgery highlights the clinical benefits of treating patients with Lombard Medical’s Aorfix endovascular stent graft.
Early experience with a device that allows the preservation of the hypogastric artery during endovascular treatment of iliac artery aneurysms shows that the endograft is safe and effective, with a high success rate and patency of over 90% at six months. Results with the new Iliac Branch Excluder were presented at the Vascular Annual Meeting (17–20 June, Chicago, USA).
A new study shows that positron emission tomography-computed tomography (PET-CT) can be performed in peripheral arteries “with strong reliability”, according to the investigators. They say also that their results may provide early evidence of possible links between calcification and inflammatory processes occurring within the lower limb arterial tree.
Use of mechanical thrombectomy on qualifying stroke patients could result in major savings to the healthcare economy in the United Kingdom and other western countries with a similar healthcare structure, according to a new study presented at the Society of NeuroInterventional Surgery 12th Annual Meeting in San Francisco, USA.
In the last decade, intra-arterial stroke therapy (in which thrombolytic agents and devices are passed through the arteries directly to the clot site) has gained notable momentum as an effective and safe treatment option for patients. Two new studies released at the Society of NeuroInterventional Surgery 12th Annual Meeting (27–30 July, San Francisco, USA) further reinforce the value and progress of intra-arterial treatment and conclude that the new devices that facilitate this approach are reducing treatment times, improving outcomes and decreasing mortality rates.
The US FDA has approved the Reshape Integrated Dual Balloon System (ReShape). The system is a temporary weight-loss system of gastric balloons that are placed in a minimally invasive manner to occupy space in the stomach. They should be removed after six months.
Lombard Medical announced on 30 July 2015 the acquisition of Silicon Valley-based Altura Medical, a privately-held, venture-backed company that has developed an innovative ultra-low profile endovascular stent graft technology that, according to Lombard, offers a simple and predictable solution for the treatment of standard abdominal aortic aneurysm anatomies.
Eximo Medical has completed its series A funding round of US$1.6 million. Accelmed, a medical device Investment Fund, led the round, with the participation of the Alfred Mann Institute at the Technion (AMIT), the Technion R&D Foundation Ltd and a private investor.
Boston Childrens Hospital physicians report the first cases of children benefitting from 3D printing of their anatomy before undergoing high-risk brain procedures. The four children had life-threatening cerebrovascular malformations that posed special treatment challenges.
The US Centers for Medicare and Medicaid Services (CMS) has approved a new technology add-on payment for Bard’s Lutonix drug-coated balloon under the Medicare hospital inpatient prospective payment system.
Newly published research has documented the ability of Teleflex Incorporated’s Arrow central venous catheter (CVC) with ARROWg+ard Blue Technology to reduce both catheter-related bloodstream infections and direct costs associated with treating those infections, even when the infection risk is already low.
Gore has applauded the recent reclassification of endovascular abdominal aneurysm repair (EVAR) by the Centers for Medicare and Medicaid Services (CMS) to a new Medicare Severity Diagnosis-Related Group (MS-DRG) classification that will result in an increase in the hospital reimbursement for these procedures.
Cookies Sociales
Son esos botones que permiten compartir el contenido del sitio web en sus redes sociales (Facebook, Twitter y Linkedin, previo tu consentimiento y login) a través de sistemas totalmente gestionados por dichas redes sociales, así como los recursos (pej. videos) y material que se encuentra en nuestra web, y que de igual manera se presta y gestiona completamente por un tercero.
Si no acepta estas cookies, no podrá compartir nuestro contenido a través de los botones, y en su caso, no podrás visualizar el contenido de terceros que hayamos incrustado en el sitio.
No las utilizamos